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Introduction
Oxytocin (OT) biosynthesis is not restricted to the hypothalamus as previously assumed. Other areas in the brain and several peripheral organs express OT and OT receptor (OTR) genes (reviewed in Ivell and Russell, 1995) . OT has been shown to have a wider range of physiological actions than stimulation of milk ejection and uterine contractions. Among peripheral actions, regulation of luteal function by OT in ruminants and other ungulates has attracted much attention (reviewed in Flint et al., 1992) . In these species, corpus luteum expresses high levels of OT gene and a feedback loop exists between luteal OT, endometrial OTR and PGF 2a released from the endometrium under the influence of OT. Removal of the uterus disrupts normal ovarian cyclicity in these species (Ginther, 1974) , whereas in primates ovarian activity is not affected by hysterectomy (Neill et al., 1969; Beling and Marcus, 1970) . Because human non-pregnant endometrium has the capacity to synthesize prostanoids from endogenous precursors (Smith and Kelly, 1988) and OT has the ability to stimulate prostaglandin release from pregnant human decidua (Fuchs et al., 1981 (Fuchs et al., , 1984 , the failure of hysterectomy to affect luteal function in non-pregnant women might be due to lack of endometrial OTR.
The purpose of our study was to determine whether OTR and vasopressin receptors (VPR) are present in endometrium from non-pregnant women and rhesus monkeys at different stages of the menstrual cycle, and to characterize the receptors in regard to ligand specificity. Because OT and arginine vasopressin (AVP) receptors in human myometrium show relatively low selectivity towards the two neurohormones (Tence et al., 1990; Maggi et al., 1992) , the concentrations of each receptor and their regulation in non-pregnant myometrium are still controversial. We have therefore used a novel, selective antagonist of VP 1 subtype receptor, iodo-linear vasopressin antagonist (I-LVA) (Barberis et al., 1995) , to measure vasopressin receptor concentrations in myometrium and fibromyomas. For comparison, tissues from three stages of pregnancy were also examined. The localization of OTR protein was determined in non-pregnant human uterine tissues by immunohistochemistry.
Investigations on endometrial oxytocin and vasopressin receptors Patients and preparation of tissue
A total of 45 women (age range 34-50 years) who underwent hysterectomy for various non-malignant uterine diseases gave permission to take samples of myometrium, endometrium and fibromyomas. The study was approved by the Institutional Human Rights Committee. Of the women, 42 were premenopausal, and none suffered from endometriosis. One of the subjects was receiving tamoxifen for treatment of breast cancer. The day of the cycle was known in all cases; hormonal status was verified by endometrial histology. Three pregnant women who underwent hysterectomy for medical indications at 5, 13 or 35 weeks of gestational age were included for comparison. Endometrial biopsies were obtained from non-pregnant rhesus monkeys at days 9, 14 and 23 of the cycle (three each), and both endometrium and myometrium were taken from three rhesus monkeys after hysterectomy performed in the luteal phase; endometrial and myometrial biopsies were also obtained from five pregnant monkeys (100-130 days of gestational age).
In humans, normal tissue was dissected from the corpus and fundus within 15 min of removal of the uterus. The samples were immediately frozen in liquid nitrogen and kept at -70°C until further processed. A crude membrane fraction was prepared by sequential centrifugation of tissue homogenates. The fraction precipitating between 1000 g (10 min) and 160 000 g (30 min) was used for the assays as previously described (Fuchs et al., 1990) . The concentrations of protein in the membrane fraction and DNA in the low speed pellet were measured as previously described (Fuchs et al., 1990) . The membrane preparations were stored at -70°C suspended in Ca 2+ -free Krebs bicarbonate buffer (pH 7.4) containing 0.002% phenyl methyl sulphonyl fluoride (PMSF).
Molecular and immunohistochemical analyses
Receptor assay
Saturation experiments with 6-10 different concentrations of labelled ligand were carried out using 0.5-1 mg/ml protein suspended in 0.05 Tris maleate buffer (pH 7.4) that contained 5 mM MnCl and 0.002% PMSF in a total volume of 220 µl as previously described (Fuchs et al., 1990) . Incubation was carried out at 22°C for 60 min and separation of bound from free ligand was performed by rapid filtration through Whatman CF/F filters using a cell harvester (Braendel, Gaithersburgh, MD, USA). Ligand specificity was determined in competition experiments performed with pooled membrane preparations from 3-4 subjects in secretory phase, using ~1 nM labelled ligand and 10 or 11 different concentrations of unlabelled agonists or antagonists. Aliquots of a membrane preparation with known receptor concentrations were used as quality controls in each experiment. All measurements were done in duplicate. Tritiated oxytocin ([ 3 H]OT) and arginine vasopressin ([ 3 H]AVP) (New England Nuclear, Boston, MA, USA), were used as labelled ligands in concentrations ranging from 10 -10 to 10 -8 M. In addition, a novel, linear VP 1a/1b antagonist (Barberis et al., 1995) , HO-Phaa-D-Tyr(Me)-Phe-Gln-Asn-Arg-Pro-Arg-NH 2 (HO)-LVA 1 , courtesy of Dr M.Manning (Medical College of Ohio, Toledo, OH, USA), was iodinated and used as labelled ligand (10 -12 to 5 × 10 -10 M) for membrane preparations from the subjects for which enough tissue was available (n = 27). Iodination of the peptide was performed using Na 125 I (Amersham, Arlington, IL, USA) and iodogen beads (Pierce Chemical Co., Rockford, IL, USA).
[ 125 I]LVA was purified on Sephadex 25 columns and treated with Rexyn beads to absorb excess Na 125 I. Unlabelled OT, arginine vasopressin and another VP 1 receptor antagonist, [1-(β-mercapto-β,β-cyclopentamethylene-propionic acid,2-(O-methyl)tyrosine]-argininevasopressin ('Manning compound', MC), arginine vasotocin (AVT), and isotocin (IT), the most specific natural oxytocic analogue, were obtained from Bachem (Torrance, CA, USA). Other agonists and antagonist used in competition experiments were a specific OT antagonist, [1-(β-mercapto-β,β-cyclopentamethylene-propionic acid, 2-(O-methyl) tyrosine,4-threonine,9-tyrosine-NH 2 ]-vasotocin, (OTA), a gift from Dr M.Manning; a specific AVP receptor V 1 subtype agonist, (2-phenylalanine,3-isoleucine,9-ornithine)vasopressin (PAVP), from Peninsula Labs (Belmont, CA, USA), and a specific AVP receptor V 2 subtype agonist, [1-desamino,8-D-arginine] vasopressin (DDAVP), which together with other chemicals was obtained from Sigma (St. Louis, MO, USA).
Immunohistochemical localization of human OTR
A monoclonal antibody was used to identify the cellular localization of the receptor protein in endometrial and myometrial tissues. The antibody, 2F8, was developed by Takemura et al. (1993) in mice against a 21-amino acid peptide sequence comprising the extracellular, amino-terminal region of the human OT receptor gene. Frozen cryostat sections (7 µm) from each tissue were mounted on gelatine-coated slides. Sections were fixed in cold methanol (-20°C) and then air dried before immunostaining. Antibodies were applied at different dilutions (1:100, 1:500, 1:1000, 1:2000). Immunoenzymatic labelling was carried out using the alkaline phosphatase technique (APAAP-complex; Dianova, Hamburg, Germany). The specificity of staining was monitored in control sections where the hormone-specific antibody was replaced by equivalent amount of pure mouse IgM. After counterstaining with haematoxylin, all sections were mounted in glycerine jelly and examined through a Nikon Epiphot (Nikon Inc, Melville, NJ, USA) microscope. Muscle tissue from the jaw was used as a negative control tissue.
Statistical analysis
The data from saturation and competition experiments were analysed by a computerized itinerating curve fitting program (Ligand; Biosoft, Cambridge, UK), which calculated the binding parameters non-pregnant range. At 13 and 35 weeks of gestational age, the density of endometrial OTR had increased considerably, resulting in a significantly higher [OTR:VPR] ratio than in non-pregnant women, and at 35 weeks gestational age a further increase in OTR concentrations was observed in both endometrium and myometrium (Table III) . Although not identical, the values for binding capacity of [ 125 I]LVA and [ 3 H]AVP were well correlated in tissues from each subject: r = 0.792 for endometrial membranes and r = 0.747 for myometrial membranes, P < 0.002 in both instances. a Protein concentration in this instance is for pellet obtained between 20 000 and 100 000 g, which has about one-half of the concentration in the 1000 and 100 000 g pellet. * denote radioactive labelling of the compounds. Samples of fibromyoma were available from 20 of the study subjects; OTR and VPR concentrations in these specimens were similar to those in myometrium from the same women at all cycle stages examined (Table III) 
Receptor concentrations (fmol/DNA)
During the menstrual cycle, marked changes occur in the cellular characteristics of uterine tissues, particularly endometrium. Protein concentrations per unit DNA in the crude endometrial microsomal pellets varied according to the cycle stage: 24.0 ± 7.2 mg/mg DNA at early proliferative phase, 70.4 ± 14.7 mg/mg DNA at late proliferative phase, 96.0 ± 21 mg/mg DNA at early secretory phase and 49.0 ± 8.0 mg/mg DNA at late secretory phase (P < 0.02, analysis of variance). In myometrium and fibromyomas, microsomal protein concentration per mg DNA increased somewhat from the early proliferative to late secretory phase but the variations were not statistically significant, mean ± SE was 7.2 ± 0.9 mg/mg DNA for myometrium and 5. Table VII . It is pertinent to note that iodo-LVA and the non-iodinated, unlabelled LVA have somewhat different binding affinities (Barberis et al., 1995) . Iodo-LVA binds more selectively to VP 1 receptors than LVA, which in turn competes with OT binding more avidly than the iodo derivative. Binding of [ 125 I]LVA to uterine tissues from non-pregnant and pregnant women best fitted a two-site model, as did data from competition experiments with a specific VP1 antagonist, PAVP. The non-iodinated LVA competed for [ 3 H]AVP receptors with a K a of 2.0 × 10 9 l/nmol, and for [ 3 H]OT with ~5 times lower affinity, K a = 4.4 × 10 8 l/nmol, for OT receptors.
The rank order of affinities corresponded to the pharmacological potency of the analogues tested, except in non-pregnant endometrium. In this tissue, AVP and the two VP 1 -specific VP analogues competed with significantly greater affinity for [ 3 H]OT binding sites than OT and the OT-specific antagonist OTA, indicating that [ 3 H]OT most likely labels endometrial AVP sites instead of OT sites at this stage of the cycle. Human endometrial cells may therefore not express the OTR gene in the luteal phase. Human uterine OT receptors discriminated poorly between OT and AVP; the affinity of unlabelled OT for OTR was only 2-3 times higher than that of AVP, whereas they discriminated more effectively between OT and the VP 1 agonist PAVP and the antagonist MC, showing 17-fold higher selectivity for OT in both instances. Human VPR were more selective than OTR and bound AVP on the average, with 14 times higher affinity than OT. On the other hand, OTA, which in rat uterus is a highly selective OT antagonist, competed with surprisingly high affinity with both [ 3 H]AVP and [ 125 I]LVA for human uterine VPR (Table VI) Superscripts denote a high-affinity site and b low-affinity site. OTA = [1-( beta-mercapto-beta,beta-cyclopentamethylene-propionic acid,2-(O-methyl)tyrosine,4-threonine,9-tyrosine-NH 2 ]-vasotocin; OT = oxytocin; AVP = arginine vasopressin; MC = [1-( beta-mercapto-beta,beta-cyclopentamethylene-propionic acid,2-(O-methyl)tyrosine]-arginine-vasopressin ('Manning compound'); PAVP = (2-phenylalanine,3-isoleucine,9-ornithine)vasopressin; IT = isotocin. a Two-site model significantly better, B max for OT selective site was 95 ± 9.4 fmol/mg; for the AVP selective site 17.5 ± 1.7 fmol/mg. Values are for the one-site model. b Two-site possible but not significantly better than to one site, B max for OT selective site was 433 ± 9 fmol/mg; for the AVP selective site 43.5 ± 10.5 fmol/mg.
Immunohistochemistry
In human non-pregnant endometrial tissues, immunoreactive OT receptor protein (ir-OTR) was detected in a small number of epithelial cells in specimens from the early proliferative phase, faint signals could be detected in specimens from midcycle, and no signals in specimens from the late secretory phase. Immunoreactivity was not detected in other cell types (Figure 5a,b) . Ir-OTR-positive cells were more numerous in myometrium than endometrium. Many more ir-OTR-positive muscle cells were seen in the early proliferative phase and late secretory phase than in midcycle, when only a few ir-OTR-positive muscle cells were detected. Clusters of ir-positive muscle cells occurred among numerous ir-OTR-negative muscle cells (Figure 5c,d ). Blood vessel walls showed no staining for ir-OTR.
The roles of uterine receptors sites for oxytocin and vasopressin
The results obtained provide evidence for the existence of distinct binding sites for OT and AVP in non-pregnant human and rhesus endometrium, myometrium and fibromyomas. Scatchard analysis of binding data for [ 3 H]AVP revealed complex binding kinetics, and analysis of data from competition experiments with unlabelled analogues revealed interaction of OT and AVP with two independent sites. Ligand specificity of the AVP binding sites identified them as VP 1 subtype receptors, which are present on vascular smooth muscle cells and hepatocytes, and have been previously identified in human (Tence et al., 1990) , rat (Chan et al., 1990) and pregnant rabbit myometrium (Maggi et al., 1988) . It has been established that the receptor proteins for OT, VP 1 and VP 2 are encoded by separate genes. Human OT receptor gene was cloned by Kimura et al. (1992 and Takemura et al., 1993) , who demonstrated that mRNA encoding for the OT receptor gene was expressed in human uterus. The gene encoding for the human VP 1a receptor subtype has also been cloned (Thibonnier et al., 1994) , and expression of mRNA for the VP 1a receptor gene was recently demonstrated in human myometrium (Helmer et al., 1997) . VP 1 receptor mRNA was present in non-pregnant and pregnant myometrium in about equal amounts (Helmer et al., 1997) , whereas mRNA for OTR was much more abundant in pregnant than non-pregnant human uterus (Takemura et al., 1993) . These findings are in good agreement with the present results and provide conclusive evidence for the presence of separate receptors for OT and AVP in human uterine tissues.
The predominant expression of VPR rather than OTR in non-pregnant human uterus is unusual; in the uterus of most other species that have been studied to date the most abundant receptor for posterior pituitary hormones is OTR. The preponderance of VPR in uterine tissues is apparently not common for all primates; in non-pregnant rhesus monkeys, OTR and VPR concentrations in the endome- Figure 5 . Localization of immunoreactive OTR (OTR-ir) in endometrial and myometrial tissues of non-pregnant, premenopausal women obtained in early proliferative (A, E), midcycle (B, F) and late secretory phase (C, G). The alkaline phosphatase method was used. The monoclonal antibody was used at a dilution of 1:2000; controls were treated with pure mouse IgM. Staining for OTR-ir (red) was detected in relatively few epithelial endometrial (A, B) . Staining for OTR-ir was more intense in myometrial muscle cells and was present in many more cells than in endometrium; the number of OTR-ir muscle cells was much greater in late secretory phase specimens than mid-cycle specimens. trium were about equal, and OTR were more abundant than VPR in the myometrium. During pregnancy, OTR were selectively up-regulated in both species, implicating a role for progesterone or other pregnancy hormones in the up-regulation of OTR. The absence of both OTR and VPR from the endometrium of the tamoxifen-treated woman suggests a requirement for oestrogen in the expression of neurohypophysial hormone receptor genes in this tissue. The effect of oestrogens could be indirect, however, and due to induction of endometrial proliferation. This explanation is supported by the normal myometrial receptor concentration in the tamoxifen-treated woman and the down-regulation of both receptors in midcycle when circulating oestrogen concentrations are highest.
Human uterine OTR discriminate less effectively between OT and AVP than rat uterus, which is commonly used in pharmacological testing. Other differences between these species included the failure of human OTR to recognize isotocin as a highly specific oxytocic agonist and the high affinity of AVT for both human OTR and VPR. Differences have been noted among OTR gene sequences in various species (see references in Ivell and Russell, 1995) , which may explain the observed differences in the binding affinities of various analogues.
The novel VP 1 antagonist I-LVA differentiated more effectively between OT and AVP in human uterus than [ 3 H]AVP. Because of the high affinity of AVP for human uterine OTR, [ 3 H]AVP at equilibrium, as is the case in the receptor assay, will be bound to both VPR and OTR.
[ 3 H]AVP is therefore a poor ligand for quantification of VPR in human uterus. The radio-iodinated linear VP 1 antagonist was a more specific labelled ligand and therefore better suited for measurement of VPR concentrations than tritiated AVP. The non-iodinated antagonist LVA is reportedly somewhat less selective for OTR and VPR than [ 125 I]LVA (Barberis et al., 1995) .
Minor differences in ligand specificity were observed between human endometrium and myometrium. Similar differences were previously observed in pregnant and nonpregnant bovine uterine tissues (Fuchs et al., 1990) . Subtle differences may therefore exist in the gene encoding the receptor protein among different tissues within the same species. These differences could, however, also be due to differences in the lipid composition of the plasma membranes in different tissues, as suggested by Fahrenholz et al. (1995) .
The immunohistochemical findings were in good agreement with values for OT receptor density measured in saturation experiments with labelled ligands, except in the case of luteal phase endometrium. No or very little ir-OTR was observed at this stage, whereas [ 3 H]OT binding data suggested considerable up-regulation of OTR density. However, ligand specificity of [ 3 H]OT binding sites strongly suggested that the labelled OT was bound to VPR instead of OTR at this stage of the menstrual cycle. This is supported by the absence or very weak signals obtained for OTR with in-situ hybridization and polymerase chain reaction techniques in late luteal phase human endometrium (Takemura et al., 1993) . On the other hand, these authors reported finding the highest level of endometrial OTR mRNA in midcycle, which is in sharp contrast to our ligand binding and immunohistochemistry data. Their results were, however, obtained from a single patient whose menstrual stage was not verified by histology or steroid hormone determinations (T. Kimura, personal communication, 1997) . The uneven distribution of sparce OTR in human non-pregnant endometrium and myometrium may explain the great variability in OTR concentrations among samples from individuals in the same stage of menstrual cycle.
The localization of endometrial OTR in epithelial cells is of significance, since these cells are capable of releasing much more PGF 2a and PGE 2 than stromal cells in humans (Smith and Kelly, 1988) and in cows (Kim and Fortier, 1995) . Endogenous OT peptide could therefore stimulate prostaglandin release from these cells in humans, as in cows (Fuchs et al., 1995) and sheep (Flint et al., 1992) . Exogenous vasopressin infused in the late secretory phase into women elicited considerable release of PGF 2a metabolite (Strömberg et al., 1983) . Endometrial VPR in non-pregnant women are therefore likely to be localized in endometrial epithelial cells and mediate release of PGF 2a and PGE 2 . The concentration of endometrial OT and VP receptors is too low, however, to support other than local effects within the uterine lining. This may explain why the removal of the uterus has no effect on luteal function in non-pregnant women and monkeys (Neill et al., 1969; Beling et al., 1970) .
The variations in density of myometrial OTR and VPR in non-pregnant women at various stages of the menstrual cycle and during pregnancy correspond well to the differences observed in the contractile responses of the non-pregnant and pregnant human uterus to the neurohypophysial hormones (Embrey and Moir, 1967; Coutinho and Lopes, 1969; Bossmar et al., 1995) . Administration of ethanol, which inhibits release of both neurohypophysial hormones, or expansion of plasma volume, which selectively inhibits the release of AVP, result in complete suppression of uterine activity in non-pregnant women (Fuchs and Coutinho, 1971) . Neurohypophysial hormones, AVP in particular, must therefore be physiological regulators of uterine activity in non-pregnant women. The presence of high concentrations of OT and AVP receptors in uterine fibromyomas may contribute to dysmenorrhoea and the increased incidence of abortions and miscarriages in women with multiple or large myomas. Of practical interest is the possibility to study myometrial OT and AVP receptors using samples from women undergoing simple myomectomies instead of hysterectomies.
Down-regulation of OTR and VPR in very early human pregnancy has not been reported before. If confirmed, our observation suggests a role for suppression of uterine OTR and VPR in the establishment of pregnancy in women as well as in bovine and ovine species. In cows and sheep a similar phenomenon is mediated by interferon tau secreted by the conceptus (Roberts, 1989) .
Conclusion
Endometrium and myometrium of women and rhesus monkeys and fibromyomas in women contain distinct receptors for AVP and OT, and the two peptides cross-react extensively with each other's receptors. AVP receptors are predominant in non-pregnant women but not in rhesus monkeys; during the second half of pregnancy OT receptors are the most abundant of the two receptors in both species. In non-pregnant women, ir-OTR are sparsely localized in endometrial epithelial cells and in somewhat greater numbers of myometrial muscle cells; distribution of ir-OTR is uneven in both tissues. AVP receptors are of the VP 1 subtype. Receptor densities in endometrium are lower than in myometrium. OT and VP receptors per mg protein are down-regulated in midcycle and up-regulated during the secretory phase, with the exception of endometrial OTR, which disappear in the secretory phase and are up-regulated in the early proliferative phase. Unopposed oestrogen is associated with suppression and progesterone with stimulation of OT receptor expression in primate myometrium. In endometrium, progesterone may have a more complex effect, suppressing OT receptor protein in non-pregnant women and early pregnant women, while increasing OTR expression in mid-and late-pregnant women and rhesus monkeys. The regulation of VPR during pregnancy is different from OTR, and the reasons for this are not understood. The observed receptor concentrations are consistent with the contractile responses of non-pregnant and pregnant human uterus to OT and AVP in vivo. 
